Index RUT P/E - EPS (ttm) -0.73 Insider Own 5.37% Shs Outstand 205.77M Perf Week 2.40%
Market Cap 1.68B Forward P/E - EPS next Y -0.17 Insider Trans 1.49% Shs Float 195.77M Perf Month 1.25%
Income -145.93M PEG - EPS next Q -0.08 Inst Own 82.28% Short Float 12.29% Perf Quarter 26.32%
Sales 382.24M P/S 4.39 EPS this Y 64.95% Inst Trans -1.63% Short Ratio 9.35 Perf Half Y 47.72%
Book/sh -2.30 P/B - EPS next Y 59.34% ROA -29.12% Short Interest 24.06M Perf Year 14.06%
Cash/sh 1.32 P/C 6.13 EPS next 5Y 44.80% ROE - 52W Range 4.03 - 8.88 Perf YTD 35.39%
Dividend Est. - P/FCF - EPS past 5Y -3.73% ROI -42.50% 52W High -8.67% Beta 1.88
Dividend TTM - Quick Ratio 2.78 Sales past 5Y 190.00% Gross Margin 98.07% 52W Low 101.24% ATR (14) 0.31
Dividend Ex-Date - Current Ratio 2.82 EPS Y/Y TTM 43.50% Oper. Margin -15.78% RSI (14) 55.88 Volatility 3.11% 3.75%
Employees 536 Debt/Eq - Sales Y/Y TTM 24.65% Profit Margin -38.18% Recom 1.18 Target Price 14.45
Option/Short Yes / Yes LT Debt/Eq - EPS Q/Q 84.58% Payout - Rel Volume 1.41 Prev Close 8.15
Sales Surprise 11.22% EPS Surprise 65.32% Sales Q/Q 32.54% Earnings Aug 05 BMO Avg Volume 2.57M Price 8.11
SMA20 0.29% SMA50 4.76% SMA200 31.17% Trades
Volume 3,631,697 Change -0.49%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed JP Morgan
Overweight
$10
Sep-18-23 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$9 → $10
Aug-04-23 Upgrade Jefferies
Hold → Buy
$11
Jul-13-23 Upgrade BofA Securities
Neutral → Buy
$10
Feb-22-23 Upgrade Needham
Hold → Buy
$14
Nov-02-22 Upgrade Evercore ISI
In-line → Outperform
$14 → $16
Aug-05-22 Downgrade Oppenheimer
Outperform → Perform
Aug-05-22 Downgrade Evercore ISI
Outperform → In-line
$14
Apr-18-22 Downgrade Barclays
Overweight → Equal Weight
$22 → $13
Apr-11-22 Downgrade BofA Securities
Buy → Neutral
$21 → $14
Dec-10-21 Initiated Oppenheimer
Outperform
$16
Aug-06-21 Downgrade Jefferies
Buy → Hold
Aug-03-21 Initiated Cantor Fitzgerald
Overweight
$21
Mar-01-21 Initiated Cowen
Outperform
$16
Sep-29-20 Resumed JP Morgan
Overweight
$7
Jun-17-20 Initiated BTIG Research
Neutral
May-05-20 Upgrade Barclays
Equal Weight → Overweight
$7
Nov-15-19 Upgrade BofA/Merrill
Neutral → Buy
$5 → $4
May-24-19 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$16 → $4.50
Nov-16-18 Resumed Piper Jaffray
Overweight
$15
Show Previous Ratings
Sep-17-24 07:00AM
Sep-12-24 01:25AM
Sep-06-24 02:00AM
Sep-05-24 07:00AM
Sep-04-24 07:00AM
07:00AM
Loading…
Aug-22-24 07:00AM
Aug-06-24 08:45AM
Aug-05-24 01:00PM
09:55AM
08:10AM
07:06AM
(Associated Press Finance)
07:00AM
Aug-02-24 07:00AM
Jul-30-24 12:25PM
Jul-29-24 10:00AM
07:00AM
Loading…
Jul-22-24 07:00AM
Jul-18-24 12:00PM
09:55AM
Jul-10-24 04:32AM
(Pharmaceutical Technology)
Jul-09-24 07:00AM
Jul-02-24 07:00AM
Jun-04-24 07:00AM
Jun-02-24 04:00AM
May-15-24 01:13PM
11:00AM
11:00AM
11:00AM
11:00AM
May-14-24 07:00AM
May-13-24 10:31AM
07:00AM
Loading…
07:00AM
May-09-24 07:00AM
May-07-24 11:51AM
10:50AM
07:00AM
03:01AM
01:13AM
(Thomson Reuters StreetEvents)
May-06-24 06:47PM
04:59PM
01:00PM
12:35PM
12:35PM
(Associated Press Finance)
11:53AM
11:45AM
08:32AM
08:10AM
07:10AM
(Associated Press Finance)
07:00AM
May-03-24 07:00AM
Apr-29-24 10:00AM
Apr-22-24 07:00AM
Apr-17-24 05:14AM
(Pharmaceutical Business Review)
04:30AM
Apr-10-24 06:09PM
Apr-03-24 07:00AM
Mar-25-24 04:01PM
Mar-13-24 07:07AM
Mar-05-24 07:01AM
Mar-01-24 08:29AM
Feb-28-24 10:47AM
Feb-27-24 04:05AM
(Thomson Reuters StreetEvents)
Feb-26-24 04:45PM
08:10AM
07:32AM
07:09AM
(Associated Press Finance)
07:00AM
Feb-23-24 07:00AM
Feb-21-24 04:01PM
Feb-19-24 07:54AM
Feb-12-24 07:00AM
Feb-05-24 07:00AM
Feb-02-24 07:00AM
Jan-09-24 09:25AM
Jan-05-24 04:01PM
(GlobeNewswire) -5.73%
+25.62%
Jan-03-24 04:01PM
07:00AM
Dec-19-23 07:00AM
Dec-05-23 04:01PM
Nov-30-23 08:42AM
Nov-29-23 07:00AM
Nov-21-23 04:01PM
(GlobeNewswire) -5.56%
+5.29%
07:00AM
Nov-10-23 07:00AM
Nov-06-23 04:01PM
Nov-03-23 12:03PM
12:00PM
11:28AM
05:31AM
Nov-02-23 08:53AM
07:17AM
(Associated Press Finance)
07:00AM
Oct-27-23 07:00AM
Oct-26-23 07:00AM
Oct-20-23 07:00AM
Oct-19-23 07:00AM
Oct-04-23 07:00AM
Sep-18-23 07:00AM
Sep-05-23 07:00AM
Aug-28-23 08:30AM
Aug-23-23 04:01PM
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McKee Amy E Director Jun 24 '24 Sale 6.32 8,600 54,352 27,831 Jun 25 04:39 PM SANDERS MACHELLE Director Jun 17 '24 Sale 6.00 4,689 28,134 27,742 Jun 17 04:31 PM HEGGIE THERESA Director Jun 14 '24 Sale 6.11 6,698 40,925 52,852 Jun 14 04:25 PM LEVIN ALAN G Director May 30 '24 Buy 6.36 7,861 49,996 44,951 May 31 04:25 PM ASELAGE STEVE Director May 24 '24 Buy 6.40 2,500 16,000 2,500 May 29 04:16 PM Hutson Nancy J Director May 20 '24 Buy 6.38 5,000 31,900 86,818 May 22 07:24 AM MILANO VINCENT Director May 20 '24 Buy 6.25 15,000 93,750 66,997 May 22 07:21 AM Doyle Anthony Chief Financial Officer May 14 '24 Buy 5.57 36,300 202,191 266,744 May 15 07:19 AM Thackray Helen M. Chief R&D Officer May 14 '24 Buy 5.86 30,000 175,800 272,139 May 15 07:17 AM Galson Steven K Director May 13 '24 Buy 5.49 21,940 120,451 51,551 May 15 07:14 AM Barnes Alane P Chief Legal Officer May 13 '24 Buy 5.53 5,000 27,650 300,762 May 15 07:11 AM Stonehouse Jon P President & CEO May 13 '24 Buy 5.55 30,000 166,500 1,127,770 May 15 07:08 AM Gayer Charles K Chief Commercial Officer May 13 '24 Buy 5.47 30,000 164,100 307,533 May 15 07:04 AM
Index - P/E - EPS (ttm) -0.50 Insider Own 15.36% Shs Outstand 74.75M Perf Week 6.50%
Market Cap 97.92M Forward P/E - EPS next Y -0.52 Insider Trans 1.16% Shs Float 63.26M Perf Month 29.70%
Income -33.46M PEG - EPS next Q -0.12 Inst Own 21.28% Short Float 0.53% Perf Quarter 21.30%
Sales 7.52M P/S 13.02 EPS this Y 6.47% Inst Trans -7.09% Short Ratio 1.37 Perf Half Y -27.22%
Book/sh -0.38 P/B - EPS next Y -4.90% ROA -91.51% Short Interest 0.34M Perf Year 57.83%
Cash/sh 0.39 P/C 3.34 EPS next 5Y - ROE -1310.02% 52W Range 0.65 - 2.12 Perf YTD 11.97%
Dividend Est. - P/FCF - EPS past 5Y 27.88% ROI -176.65% 52W High -38.21% Beta 2.34
Dividend TTM - Quick Ratio 5.07 Sales past 5Y 1621.13% Gross Margin 96.68% 52W Low 101.51% ATR (14) 0.08
Dividend Ex-Date - Current Ratio 5.07 EPS Y/Y TTM 15.68% Oper. Margin -342.48% RSI (14) 64.72 Volatility 5.98% 6.83%
Employees 30 Debt/Eq - Sales Y/Y TTM 365.02% Profit Margin -444.66% Recom 1.00 Target Price 5.57
Option/Short Yes / Yes LT Debt/Eq - EPS Q/Q 31.21% Payout - Rel Volume 1.19 Prev Close 1.28
Sales Surprise -28.85% EPS Surprise 26.31% Sales Q/Q -91.16% Earnings Aug 12 AMC Avg Volume 244.72K Price 1.31
SMA20 18.01% SMA50 17.59% SMA200 3.24% Trades
Volume 292,366 Change 2.34%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-21-24 Initiated Chardan Capital Markets
Buy
$6
Jun-25-24 Initiated Oppenheimer
Outperform
$5
Dec-15-21 Resumed Wedbush
Outperform
$19 → $9
Jul-29-21 Initiated H.C. Wainwright
Buy
$10
May-13-20 Initiated ROTH Capital
Buy
$8
Aug-09-19 Downgrade Needham
Buy → Hold
Nov-05-18 Downgrade Stifel
Buy → Hold
Nov-05-18 Downgrade JP Morgan
Overweight → Underweight
Nov-05-18 Downgrade Cowen
Outperform → Market Perform
Mar-06-18 Reiterated Needham
Buy
$18 → $22
May-25-17 Initiated JMP Securities
Mkt Outperform
$21
Feb-24-17 Initiated JP Morgan
Overweight
$19
Nov-10-16 Reiterated Needham
Buy
$16 → $24
Oct-24-16 Reiterated Stifel
Buy
$13 → $23
Show Previous Ratings
Aug-27-24 07:05AM
Aug-15-24 09:35AM
Aug-12-24 05:25PM
04:05PM
Aug-08-24 07:05AM
10:00AM
Loading…
Aug-05-24 10:00AM
Aug-01-24 07:05AM
Jul-29-24 04:05PM
Jul-22-24 12:00PM
Jul-11-24 07:05AM
Jun-27-24 07:05AM
Jun-12-24 07:05AM
May-21-24 07:05AM
May-13-24 08:20AM
May-10-24 02:15PM
(Thomson Reuters StreetEvents) -7.41%
11:56AM
Loading…
11:56AM
May-09-24 06:55PM
04:05PM
May-08-24 04:15PM
Apr-30-24 07:05AM
Apr-16-24 07:05AM
Apr-02-24 07:05AM
Mar-18-24 07:05AM
Mar-13-24 08:30AM
06:38AM
(Thomson Reuters StreetEvents)
Mar-12-24 05:35PM
04:05PM
Mar-06-24 02:25PM
Feb-29-24 07:05AM
Feb-25-24 01:37PM
08:00AM
Loading…
Feb-07-24 08:00AM
Dec-14-23 07:05AM
Nov-14-23 09:11AM
Nov-13-23 04:05PM
Nov-08-23 07:05AM
Nov-07-23 04:20PM
Nov-03-23 12:00PM
Nov-02-23 07:05AM
Nov-01-23 07:05AM
Oct-31-23 07:05AM
Oct-26-23 12:24AM
Oct-16-23 07:05AM
Oct-04-23 09:00AM
Oct-03-23 04:35PM
Sep-19-23 07:05AM
Aug-14-23 04:05PM
Aug-02-23 04:30PM
Aug-01-23 07:05AM
Jul-31-23 07:05AM
Jul-20-23 07:05AM
Jul-11-23 04:05PM
Jul-10-23 07:05AM
Jun-29-23 09:50AM
Jun-01-23 07:05AM
May-11-23 08:25AM
07:05AM
May-09-23 04:30PM
May-02-23 07:05AM
Apr-27-23 07:05AM
Apr-18-23 07:05AM
Apr-12-23 07:05AM
Apr-09-23 09:42AM
Apr-05-23 07:05AM
Mar-11-23 03:14AM
Mar-09-23 06:35PM
04:05PM
Feb-23-23 07:05AM
Feb-21-23 07:05AM
Feb-07-23 07:05AM
Feb-06-23 07:30AM
Feb-02-23 01:18PM
07:05AM
Dec-22-22 09:52AM
05:05AM
Nov-22-22 07:05AM
Nov-11-22 05:26AM
Nov-10-22 01:24PM
07:05AM
Nov-09-22 09:05AM
07:15AM
07:05AM
Nov-08-22 04:05PM
Nov-02-22 07:05AM
Oct-31-22 08:52AM
Oct-17-22 11:27AM
Oct-04-22 07:05AM
Sep-27-22 07:05AM
Aug-25-22 07:05AM
Aug-11-22 06:21AM
Aug-09-22 08:35AM
07:05AM
Aug-08-22 04:30PM
08:05AM
Aug-03-22 07:05AM
Jul-27-22 07:05AM
Jul-26-22 07:05AM
Jul-09-22 08:25AM
Jul-07-22 07:05AM
Jun-14-22 07:05AM
Jun-08-22 07:05AM
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chong Ngai Hang Victor Chief Medical Officer Jun 24 '24 Buy 1.06 23,500 24,910 63,500 Jun 24 04:38 PM YERXA BENJAMIN R Director May 15 '24 Buy 1.31 7,813 10,235 17,957 May 15 05:28 PM Gibney Anthony S Director Apr 18 '24 Buy 1.30 93,290 121,277 100,000 Apr 19 09:45 AM Gibney Anthony S Director Apr 17 '24 Buy 1.25 6,710 8,388 6,710 Apr 19 09:45 AM Chong Ngai Hang Victor CHIEF MEDICAL OFFICER Mar 20 '24 Buy 1.60 30,000 48,000 30,000 Mar 20 04:30 PM WHITMORE BRADFORD T 10% Owner Feb 07 '24 Buy 1.35 444,444 599,999 4,495,034 Feb 09 01:00 PM LASEZKAY GEORGE M CEO Jan 19 '24 Sale 1.27 18,000 22,860 466,577 Jan 19 06:26 PM Deignan Charles A. Chief Financial Officer Jan 19 '24 Sale 1.28 12,900 16,512 384,662 Jan 19 06:25 PM WHITMORE BRADFORD T 10% Owner Oct 31 '23 Buy 0.73 70,812 51,537 3,986,224 Nov 01 04:24 PM WHITMORE BRADFORD T 10% Owner Nov 01 '23 Buy 0.74 64,366 47,901 4,050,590 Nov 01 04:24 PM WHITMORE BRADFORD T 10% Owner Oct 30 '23 Buy 0.69 600 411 3,915,412 Nov 01 04:24 PM Hutson Nancy J Director Oct 03 '23 Buy 0.86 10,000 8,600 93,000 Oct 04 05:06 PM Thorp Clay Director Sep 25 '23 Buy 0.86 10,000 8,600 40,522 Sep 25 04:34 PM Humphries William D. Director Sep 22 '23 Option Exercise 0.40 22,727 9,091 51,040 Sep 22 04:35 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
